- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02437279
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)
Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Patients with stage III melanoma with palpable disease, naïve for CTLA-4/PD-1/PD-L1 immunotherapy, will be treated either post-surgery for 12 weeks with the combination of ipilimumab+nivolumab or in a split design for 6 weeks upfront surgery and for 6 weeks postsurgery. It is a two-arm Phase 1b feasibility trial consisting of 20 patients, 10 in each arm.
At different timepoints tumor biopsies and blood for PBMCs will be taken for translational research. Also scans will be done on specific timepoints.
The study will be held to determine safety, feasibility, and the immune-activating capacity of short-term combined neo-adjuvant and adjuvant ipilimumab + nivolumab. And to determine relapse free survival (RFS), any late adverse events, pharmacokinetics/pharmacodynamics, and the correlation between RFS and changes in neo-antigen specific T cell response.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
NH
-
Amsterdam, NH, Niederlande, 1066CX
- Netherlands Cancer Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults at least 18 years of age
- World Health Organization (WHO) Performance Status 0 or 1
- Histologically confirmed stage IIIB metastatic cutaneous melanoma, palpable disease (non-transit only) of the axilla or groin
- Patient willing to undergo triple tumor biopsies during screening and in case of disease progression
- No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1
- No immunosuppressive medications within 6 months prior study inclusion
- Presence of at least two of the defined HLA alleles (Table 1, see appendix)
Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils
≥1.5x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, Creatinine ≤1.5x ULN, AST ≤1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN
- normal LDH
- Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
- Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of ipilimumab+nivolumab
- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product
- Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception
Exclusion Criteria:
- Distantly metastasized melanoma
- Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
- Prior CTLA-4 or PD-1/PD-L1 targeting immunotherapy
- Radiotherapy prior or post surgery within this trial
- Patients will be excluded if they are positive test for hepatitis B virus surface antigen (HBVsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
- Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Allergies and Adverse Drug Reaction
- History of allergy to study drug components
- History of severe hypersensitivity reaction to any monoclonal antibody
- Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events;
- Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
- Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion
- Pregnant or nursing.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Arm A
Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
|
|
Aktiver Komparator: Arm B
A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood
Zeitfenster: 12 weeks from baseline
|
To this purpose the immunogenic mutational load of each patient's melanoma will be determined by DNA and RNA sequencing from baseline biopsies (3x14g, 5ug tumor DNA).
Proteasomal degradation and peptide presentation in HLA will be predicted in silico.
MHC-tetramer staining containing the predicted peptides will be done as described before [2].
In addition, the effect of therapy on intratumoral T cell responses to obtain better insight into the mode of action of therapy will be analyzed.
Identified neo-antigen specific T cells will be analyzed with respect to their phenotype and immunologic function (intracellular cytokine staining, lytic function as determined by CD107 staining, and coculture with APC presenting the cognate antigen).
|
12 weeks from baseline
|
Safety as measured by SUSARs.
Zeitfenster: 12 weeks from baseline
|
12 weeks from baseline
|
|
The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood
Zeitfenster: 12 weeks from baseline
|
To this purpose the immunogenic mutational load of each patient's melanoma will be determined by DNA and RNA sequencing from baseline biopsies (3x14g, 5ug tumor DNA).
Proteasomal degradation and peptide presentation in HLA will be predicted in silico.
MHC-tetramer staining containing the predicted peptides will be done as described before [2].
In addition, the effect of therapy on intratumoral T cell responses to obtain better insight into the mode of action of therapy will be analyzed.
Identified neo-antigen specific T cells will be analyzed with respect to their phenotype and immunologic function (intracellular cytokine staining, lytic function as determined by CD107 staining, and coculture with APC presenting the cognate antigen).
|
12 weeks from baseline
|
Feasibility as measured adherence to the timelines in the study protocol.
Zeitfenster: 12 weeks from baseline
|
12 weeks from baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Recurrence Free Survival, as determined according to RECIST 1.1 criteria.
Zeitfenster: Until progression, median 10 months.
|
Until progression, median 10 months.
|
Rate of adverse events and late adverse events
Zeitfenster: Until end of follow-up, median 3 years.
|
Until end of follow-up, median 3 years.
|
Type of adverse events and late adverse events
Zeitfenster: Until end of follow-up, median 3 years.
|
Until end of follow-up, median 3 years.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Christian Blank, MD PhD, The Netherlands Cancer Institute
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Versluis JM, Reijers ILM, Rozeman EA, Menzies AM, van Akkooi ACJ, Wouters MW, Ch'ng S, Saw RPM, Scolyer RA, van de Wiel BA, Schilling B, Long GV, Blank CU. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer. 2021 May;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Epub 2021 Mar 15.
- Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, Blank CU. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021 Feb;27(2):256-263. doi: 10.1038/s41591-020-01211-7. Epub 2021 Feb 8.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neuroendokrine Tumoren
- Nävi und Melanome
- Melanom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Antineoplastische Mittel, immunologische
- Immun-Checkpoint-Inhibitoren
- Nivolumab
- Ipilimumab
Andere Studien-ID-Nummern
- N14OPC
- CA209-278 (Andere Zuschuss-/Finanzierungsnummer: BMS)
- NL51280.031.14 (Registrierungskennung: CCMO register)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Surgery of the tumor
-
Memorial Sloan Kettering Cancer CenterBeendetDie Familien oder nächsten Angehörigen von Patienten, die am MSKCC wegen nichtkutaner Plattenepithelkarzinome behandelt wurden | Oberer AerodigestivtraktVereinigte Staaten
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... und andere MitarbeiterAbgeschlossenEierstockkrebs | Eileiterkrebs | PeritonealhöhlenkrebsSpanien, Frankreich, Dänemark, Belgien, Deutschland, Österreich, China, Italien, Korea, Republik von, Norwegen, Schweden, Vereinigtes Königreich
-
Skin Analytics LimitedAbgeschlossenBasalzellkarzinom | Plattenepithelkarzinom | Malignes Hautmelanom T0Vereinigte Staaten, Italien
-
Skin Analytics LimitedInnovate UKAbgeschlossen
-
Skin Analytics LimitedInnovate UKAbgeschlossen
-
Buddhist Tzu Chi General HospitalAbgeschlossen
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnbekanntHändewaschenNiederlande
-
Duke UniversityNational Institute of Mental Health (NIMH); National Institute for Medical Research... und andere MitarbeiterRekrutierungAdhärenz, Medikamente | HIV-1-Infektion | Problem der psychischen GesundheitTansania
-
Buddhist Tzu Chi General HospitalRekrutierung
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...RekrutierungCOVID-19 | Magen-Darm-BlutungenKanada